<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="65474">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01942538</url>
  </required_header>
  <id_info>
    <org_study_id>2013-A00820-45</org_study_id>
    <nct_id>NCT01942538</nct_id>
  </id_info>
  <brief_title>Efficiency of Repetitive Transcranial Magnetic Stimulation (rTMS) Sessions After a Successful 3 Week-treatment in Fibromyalgia</brief_title>
  <official_title>Study of the Effectiveness of Maintenance rTMS Sessions for 6 Months Versus Placebo in Subjects With Fibromyalgia Responders to 3 Week-rTMS Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Esquirol</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Esquirol</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>France: Committee for the Protection of Personnes</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Maintenance rTMS sessions after a successful 3week-rTMS treatment for subjects with
      fibromyalgia may maintain the clinical improvement.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In a previous pilot study, a 3 week treatment with rTMS in fibromyalgia subjects induced a
      40% improvement of pain feeling. Three months later, the pain level was still significantly
      reduced in comparison with the beginning of the treatment, but the clinical improvement was
      less than at the end of the treatment. We thus propose to realize real or sham rTMS sessions
      at 3 weeks interval during 6 months with subjects presenting a significant clinical
      improvement after a 3 week-rTMS or sham treatment to evaluate the response maintenance.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>number of fibromyalgia subjects maintaining a clinical improvement with rTMS maintenance sessions during 6 months</measure>
    <time_frame>210 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>= number of fibromyalgia subjects maintaining a clinical improvement after a prior rTMS treatment (15 sessions in 3 weeks)and maintenance rTMS sessions administered at 42, 63, 84, 105, 126, 147, 168, 189, 210 days after inclusion in comparison with sham maintenance sessions.
clinical improvement is described as a 30% decrease from baseline in pain feeling (visual analogue scale) and a response ≥ 6 for the Patient's global impression of Change.
effect will be considered as maintained if criteria of clinical improvement present after 3 week rTMS treatment are conserved at 6 months rTMS or sham maintenance sessions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of rTMS responders at 3week-rTMS treatment</measure>
    <time_frame>21 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Fibromyalgia</condition>
  <arm_group>
    <arm_group_label>rTMS-rTMS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects receiving real rTMS treatment and real rTMS maintenance sessions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sham - sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>subjects receiving sham treatment and presenting a clinical improvement : they will be submitted to sham maintenance sessions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rTMS-sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>subjects receiving sham rTMS maintenance sessions after successful real rTMS treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rTMS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>real rTMS for 3 weeks but without clinical improvement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>sham treatment for 3 weeks without clinical improvement</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>rTMS</intervention_name>
    <description>one session : 20 runs of 10 seconds high frequency stimulation(10Hz) and 50 seconds pause - power equivalent to 90% of the motor threshold</description>
    <arm_group_label>rTMS-rTMS</arm_group_label>
    <arm_group_label>rTMS-sham</arm_group_label>
    <arm_group_label>rTMS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>sham rTMS</intervention_name>
    <description>same session as defined with the real rTMS, but with a coil not delivering magnetic field.</description>
    <arm_group_label>sham - sham</arm_group_label>
    <arm_group_label>rTMS-sham</arm_group_label>
    <arm_group_label>sham</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  presence of the criteria from the American College of Rheumatology (2010)for
             fibromyalgia diagnosis,

          -  painful state for more than six months,

          -  visual analogic scale evaluation &gt; or = 5,

          -  age between 18 and 70,

          -  no modification in therapeutic treatment one month before and during the protocol

          -  presence of actual or prior antalgic chronic treatment : pregabalin, duloxetine,
             milnacipran, gabapentin, venlafaxine, laroxyl, grade 1 or 2 antalgic

          -  residence in Limoges or the periphery, or the ability to come to the hospital for the
             treatment

        Exclusion Criteria:

          -  presence of non stabilized psychiatric comorbidity (personality trouble, addiction,
             suicide attempt, non controlled affective trouble),

          -  active epilepsy,

          -  previous cerebral traumatism, or cerebral surgery, intra-cranial hyper tension,

          -  pacemaker, metallic pieces in the brain, cochlear ocular implant, or any metallic
             material contra indicating magnetic resonance imaging.

          -  clozapine, bupropion, methadon, theophyllin, or other non chemical antalgic technic
             established during the previous month(kinesitherapy, relaxation, hypnosis...),

          -  pregnancy, or administrative and judiciary protection, absence of health insurance.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Christophe Dumont, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Dupuytren CH Esquirol</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Christophe Dumont, MD</last_name>
    <phone>0033555056870</phone>
    <email>j.christophe.dumont@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Murielle Girard, PhD</last_name>
    <phone>0033555431028</phone>
    <email>murielle.girard@ch-esquirol-limoges.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Esquirol</name>
      <address>
        <city>Limoges</city>
        <zip>87000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dominique Malauzat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire</name>
      <address>
        <city>Limoges</city>
        <zip>87000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pascale Vergne-Salle, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe Bertin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Ciobanu C, Girard M, Marin B, Labrunie A, Malauzat D. rTMS for pharmacoresistant major depression in the clinical setting of a psychiatric hospital: Effectiveness and effects of age. J Affect Disord. 2013 Sep 5;150(2):677-81. doi: 10.1016/j.jad.2013.03.024. Epub 2013 May 11.</citation>
    <PMID>23673085</PMID>
  </reference>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 20, 2014</lastchanged_date>
  <firstreceived_date>September 11, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Esquirol</investigator_affiliation>
    <investigator_full_name>Jean-Christophe Dumont</investigator_full_name>
    <investigator_title>Medical Doctor, Assistant in Rheumatologia Service  CHU Limoges</investigator_title>
  </responsible_party>
  <keyword>rTMS</keyword>
  <keyword>fibromyalgia</keyword>
  <keyword>sham</keyword>
  <keyword>maintenance session</keyword>
  <keyword>pain</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
